2015 Peel Street
11th Floor
Montreal, QC H3A 1T8
Canada
https://www.theratech.com
Sector(s):Â Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees:Â 87
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Paul Lévesque | Pres, CEO & Director | 1.24M | N/A | 1964 |
Mr. Philippe Dubuc M.B.A., MBA | Sr. VP & CFO | 393.59k | N/A | 1967 |
Dr. Christian Marsolais Ph.D. | Sr. VP & Chief Medical Officer | 383.71k | N/A | 1963 |
Mr. John Leasure | Global Commercial Officer | 353.81k | N/A | 1965 |
Ms. Elif McDonald | Sr. Director of Investor Relations | N/A | N/A | N/A |
Mr. Jocelyn Lafond L.L.M., LL.B. | Gen. Counsel & Corp. Sec. | N/A | N/A | 1968 |
Mr. Denis Boucher B.A., L.L.B. | VP of Communications & Corp. Affairs | N/A | N/A | 1966 |
Hon. Andre Dupras | VP of HR | N/A | N/A | 1964 |
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Theratechnologies Inc.’s ISS Governance QualityScore as of June 1, 2022 is 7. The pillar scores are Audit: 9; Board: 6; Shareholder Rights: 9; Compensation: 7.